About EpilepsyGTx
EpilepsyGTx is a company based in Waterbeach (United Kingdom) founded in 2021. EpilepsyGTx has raised $43 million across 2 funding rounds from investors including UCL Technology Fund and HTH. EpilepsyGTx offers products and services including EPY201. EpilepsyGTx operates in a competitive market with competitors including Biological E, Vir Biotechnology, Vaxcyte, Cidara Therapeutics and Marinus Pharma, among others.
- Headquarter Waterbeach, United Kingdom
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$43 M (USD)
in 2 rounds
-
Latest Funding Round
$33 M (USD), Series A
Dec 09, 2025
-
Investors
UCL Technology Fund
& 1 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of EpilepsyGTx
EpilepsyGTx offers a comprehensive portfolio of products and services, including EPY201.
Targets seizure focus in focal refractory epilepsy for potential treatment.
Funding Insights of EpilepsyGTx
EpilepsyGTx has successfully raised a total of $43M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $33 million completed in December 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in EpilepsyGTx
EpilepsyGTx has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include UCL Technology Fund and HTH.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on physical and life sciences companies
|
Locked | Locked | Locked | |
|
HTH is engaged in investing in health technology startups.
|
Locked | Locked | Locked |
Investor details for EpilepsyGTx
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by EpilepsyGTx
Investment portfolio details for EpilepsyGTx
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - EpilepsyGTx
Detailed financials for EpilepsyGTx
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Epilepsygtx Comparisons
Peer comparison for EpilepsyGTx
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of EpilepsyGTx
EpilepsyGTx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biological E, Vir Biotechnology, Vaxcyte, Cidara Therapeutics and Marinus Pharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Vaccines and therapeutics for multiple diseases are developed and marketed.
|
|
| Locked | Locked | Locked |
Developer of therapeutics for the treatment of infectious diseases
|
|
| Locked | Locked | Locked |
Vaccines for infectious diseases are developed using cell-free protein synthesis.
|
|
| Locked | Locked | Locked |
Novel anti-infectives for bacterial and fungal infections are developed.
|
|
| Locked | Locked | Locked |
Developer of therapeutics to treat seizure disorders
|
|
| Locked | Locked | Locked |
Gene therapy platform is developed for chronic disease treatments.
|
Detailed competitors of EpilepsyGTx
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Epilepsygtx
Complete news archive for EpilepsyGTx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about EpilepsyGTx
EpilepsyGTx was founded in 2021 and raised its 1st funding round 3 years after it was founded.
EpilepsyGTx is headquartered in Waterbeach, United Kingdom. It is registered at Waterbeach, Cambridgeshire, United Kingdom.
Nicolas Koebel is the current CEO of EpilepsyGTx.
EpilepsyGTx is a funded company, having raised a total of $43M across 2 funding rounds to date.
EpilepsyGTx was founded in 2021 in Waterbeach, United Kingdom, as a biotechnology firm focused on gene therapies for focal refractory epilepsy. The companys primary program, EPY201, is based on an AAV9 capsid vector carrying an engineered Kv1.1 potassium channel under a CAMK2A promoter. This therapy is administered directly into the seizure focus via intraparenchymal delivery to target neurological activity. Operations center on advancing clinical-stage interventions in the neurology sector.
EpilepsyGTx's top competitors include Vaxcyte, Serum Institute of India and Biological E.
EpilepsyGTx offers EPY201.
EpilepsyGTx has 2 investors. Key investors include UCL Technology Fund, and HTH.